Are LABA/LAMA/ICS FDCS A Triple Threat for COPD Competitors in the Cost-Constrained EU5?
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.1517
https://www.valueinhealthjournal.com/article/S1098-3015(17)31851-X/fulltext
Title :
Are LABA/LAMA/ICS FDCS A Triple Threat for COPD Competitors in the Cost-Constrained EU5?
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31851-X&doi=10.1016/j.jval.2017.08.1517
First page :
A650
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1366